Peter Gibbs
Affiliations: | mskcc, New York, NY, United States |
Area:
mriGoogle:
"Peter Gibbs"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Degeling K, To YH, Trapani K, et al. (2024) PRIMCAT-CRC: a data-driven whole disease simulation model for predicting the number of colorectal cancer patients by stage and treatment line in Australia. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research |
| Piercey O, Wong HL, Leung C, et al. (2024) Adjuvant Chemotherapy for Older Patients With Stage III Colorectal Cancer: A Real-World Analysis of Treatment Recommendations, Treatment Administered and Impact on Cancer Recurrence. Clinical Colorectal Cancer |
| Mattox AK, Douville C, Wang Y, et al. (2023) The origin of highly elevated cell-free DNA in healthy individuals and patients with pancreatic, colorectal, lung, or ovarian cancer. Cancer Discovery |
| Loft M, To YH, Gibbs P, et al. (2023) Clinical application of circulating tumour DNA in colorectal cancer. The Lancet. Gastroenterology & Hepatology. 8: 837-852 |
| Conduit C, Lewin J, Weickhardt A, et al. (2023) Patterns of Relapse in Australian Patients With Clinical Stage 1 Testicular Cancer: Utility of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Surveillance Recommendations. Jco Oncology Practice. OP2300191 |
| To YH, Degeling K, McCoy M, et al. (2022) Real-world adjuvant chemotherapy treatment patterns and outcomes over time for resected stage II and III colorectal cancer. Asia-Pacific Journal of Clinical Oncology |
| Loft M, Shapiro J, Lee M, et al. (2022) Compliance with Therapeutic Goods Association prescribing information: weekly or second weekly cetuximab for the treatment of metastatic colorectal cancer. Internal Medicine Journal |
| Downie JM, Riaz M, Xie J, et al. (2022) Incident Cancer Risk and Signatures Among Older MUTYH Carriers: Analysis of Population-Based and Genomic Cohorts. Cancer Prevention Research (Philadelphia, Pa.) |
| Diaz LA, Shiu KK, Kim TW, et al. (2022) Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. The Lancet. Oncology |
| Dunn C, Hong W, Gibbs P, et al. (2021) Personalizing First-Line Systemic Therapy in Metastatic Colorectal Cancer: Is There a Role for Initial Low-Intensity Therapy in 2021 and Beyond? A Perspective From Members of the Australasian Gastrointestinal Trials Group. Clinical Colorectal Cancer |